A 12-month clinical investigation with a 24-day regimen containing 15 microg ethinylestradiol plus 60 microg gestodene with respect to hemostasis and cycle control (Q43774215)

From Wikidata

Jump to navigation Jump to search

scientific article published in June 2001

Language	Label	Description	Also known as
English	A 12-month clinical investigation with a 24-day regimen containing 15 microg ethinylestradiol plus 60 microg gestodene with respect to hemostasis and cycle control	scientific article published in June 2001

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

A 12-month clinical investigation with a 24-day regimen containing 15 microg ethinylestradiol plus 60 microg gestodene with respect to hemostasis and cycle control (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

author name string

Fruzzetti F

1

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Genazzani AR

2

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Ricci C

3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

De Negri F

4

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Bersi C

5

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Carmassi F

6

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

publication date

1 June 2001

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

63

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

303-307

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Oral contraceptives, clotting factors, and thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900213-X

7 January 2021

Fibrinopeptide A plasma levels during low-estrogen oral contraceptive treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900213-X

7 January 2021

Evaluation of the prethrombotic state in pregnancy and in women using oral contraceptives

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900213-X

7 January 2021

Effects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young women

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900213-X

7 January 2021

A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900213-X

7 January 2021

Hormone replacement therapy and hemostasis: principles of a complex interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900213-X

7 January 2021

A randomized controlled double-blind study of the effects on hemostasis of two progestogen-only pills containing 75 microgram desogestrel or 30 microgram levonorgestrel

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900213-X

7 January 2021

A comparative study on the effects of a monophasic pill containing desogestrel plus 20 μg ethinylestradiol, a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900213-X

7 January 2021

The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900213-X

7 January 2021

Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900213-X

7 January 2021

Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 microg levonorgestrel and 20 microg ethinyl estradiol (Alesse). North american Levonorgestrel Study Group (NALSG).

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900213-X

7 January 2021

A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle contr

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900213-X

7 January 2021

A comparative study of the effects of gestodene 60 microg/ethinylestradiol 15 microg and desogestrel 150 microg/ethinylestradiol 20 microg on hemostatic balance, blood lipid levels and carbohydrate metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2801%2900213-X

7 January 2021

Identifiers

10.1016/S0010-7824(01)00213-X

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43774215&oldid=2172539951"